Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 11, 2008

Nonprofit Organization Receives License for Anti-HIV Candidate from Merck & Co.

  • Merck & Co. will provide a royalty-free license to the International Partnership for Microbicides (IPM) to develop an antiretroviral compound for use as a vaginal microbicide.

    The compound, called L'644, is a member of a class of antiretroviral molecules known as gp41 fusion inhibitors, which inhibit HIV infection by preventing the virus from fusing with the surface of target cells.

    Under the terms of the agreement, Merck grants IPM the rights to develop L'644 in developing countries. The firm will collaborate with IPM to advance early-stage development research efforts.

  • You’re all set! Thank you for subscribing to GEN Highlights.